MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION: Form 990, tax year 2020

View the entire original 990 at ProPublica ↗

Organization
MARC LUSTGARTEN PANCREATIC CANCER FOUNDATION (EIN 31-1611837)
Tax period
2020-07-01 to 2021-06-30
Filed
2022-05-16
IRS object ID
202221369349304672
Schema version
2020v4.2
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Return2022-05-16T10:23:50-05:00ReturnTs
Tax Period End2021-06-30TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

FieldValueIRS element (for citing)
Preparer Firm EIN135565207PreparerFirmEIN

Preparer Firm Name PreparerFirmName

FieldValueIRS element (for citing)
Business Name Line1KPMG LLPBusinessNameLine1Txt

Preparer US Address PreparerUSAddress

FieldValueIRS element (for citing)
Address Line1550 S HOPE ST STE 1500AddressLine1Txt
CityLOS ANGELESCityNm
State AbbreviationCAStateAbbreviationCd
ZIP90071ZIPCd
FieldValueIRS element (for citing)
Return Type990ReturnTypeCd
Tax Period Begin2020-07-01TaxPeriodBeginDt

Filer Filer

FieldValueIRS element (for citing)
EIN311611837EIN

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1MARC LUSTGARTEN PANCREATIC CANCERBusinessNameLine1Txt
Business Name Line2FOUNDATIONBusinessNameLine2Txt
FieldValueIRS element (for citing)
Business Name ControlMARCBusinessNameControlTxt
Phone5167371550PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1415 CROSSWAYS PARK DRIVE SUITE DAddressLine1Txt
CityWOODBURYCityNm
State AbbreviationNYStateAbbreviationCd
ZIP11797ZIPCd

Business Officer BusinessOfficerGrp

FieldValueIRS element (for citing)
PersonLINDA TANTAWIPersonNm
Person TitleCEOPersonTitleTxt
Phone5167371550PhoneNum
Signature2022-05-16SignatureDt
Discuss With Paid PreparerYes (1)DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

FieldValueIRS element (for citing)
Person FirstLINDAPersonFirstNm
Person LastTANTAWIPersonLastNm
FieldValueIRS element (for citing)
SSN999009999SSN

Preparer Person PreparerPersonGrp

FieldValueIRS element (for citing)
Preparer PersonPABLO CORAPreparerPersonNm
PTINP01721022PTIN
Phone2139724000PhoneNum
Preparation2022-05-13PreparationDt

Additional Filer Information AdditionalFilerInformation

Trusted Customer TrustedCustomerGrp

FieldValueIRS element (for citing)
Trusted Customer0TrustedCustomerCd
Authentication Assurance LevelAAL1AuthenticationAssuranceLevelCd
Identity Assurance LevelIAL1IdentityAssuranceLevelCd
FieldValueIRS element (for citing)
Tax2020TaxYr
Build TS2022-09-23 18:48:47ZBuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

FieldValueIRS element (for citing)
Business Name Line1CURE PANCREATIC CANCER LUSTGARTEN FOBusinessNameLine1Txt
FieldValueIRS element (for citing)
Principal OfficerLINDA TANTAWIPrincipalOfficerNm

US Address USAddress

FieldValueIRS element (for citing)
Address Line1415 CROSSWAYS PARK DR SUITE DAddressLine1Txt
CityWOODBURYCityNm
State AbbreviationNYStateAbbreviationCd
ZIP11797ZIPCd
FieldValueIRS element (for citing)
Gross Receipts$95,900,067GrossReceiptsAmt
Group Return For Affiliates0GroupReturnForAffiliatesInd
Organization501c3Yes (X)Organization501c3Ind
Website AddressWWW.LUSTGARTEN.ORGWebsiteAddressTxt
Type Of Organization CorpYes (X)TypeOfOrganizationCorpInd
Formation1998FormationYr
Legal Domicile StateNYLegalDomicileStateCd
Activity Or MissionTHE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER BY FUNDING SCIENTIFIC AND CLINICAL RESEARCH RELATED TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF PANCREATIC CANCER; PROVIDING RESEARCH INFORMATION AND CLINICAL SUPPORT SERVICES TO PATIENTS, CAREGIVERS AND INDIVIDUALS AT HIGH RISK; AND INCREASING PUBLIC AWARENESS AND HOPE FOR THOSE DEALING WITH THIS DISEASE. SINCE ITS INCEPTION, THE LUSTGARTEN FOUNDATION HAS DIRECTED MORE THAN $225 MILLION TO RESEARCH AND HAS ASSEMBLED THE BEST SCIENTIFIC MINDS WITH THE HOPE THAT ONE DAY, A CURE CAN BE FOUND.ActivityOrMissionDesc
Voting Members Governing Body15VotingMembersGoverningBodyCnt
Voting Members Independent14VotingMembersIndependentCnt
Total Employee25TotalEmployeeCnt
Total Volunteers150TotalVolunteersCnt
Total Gross UBI$0TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm$0NetUnrelatedBusTxblIncmAmt
PY Contributions Grants$13,046,433PYContributionsGrantsAmt
CY Contributions Grants$15,661,608CYContributionsGrantsAmt
PY Program Service Revenue$0PYProgramServiceRevenueAmt
CY Program Service Revenue$0CYProgramServiceRevenueAmt
PY Investment Income$2,409,428PYInvestmentIncomeAmt
CY Investment Income$7,644,241CYInvestmentIncomeAmt
PY Other Revenue-$489,227PYOtherRevenueAmt
CY Other Revenue$1,161,984CYOtherRevenueAmt
PY Total Revenue$14,966,634PYTotalRevenueAmt
CY Total Revenue$24,467,833CYTotalRevenueAmt
PY Grants And Similar Paid$18,894,873PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid$15,742,900CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members$0PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members$0CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid$2,890,871PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid$3,030,185CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns$385,093PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns$697,612CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense$2,427,517CYTotalFundraisingExpenseAmt
PY Other Expenses$2,691,944PYOtherExpensesAmt
CY Other Expenses$2,255,332CYOtherExpensesAmt
PY Total Expenses$24,862,781PYTotalExpensesAmt
CY Total Expenses$21,726,029CYTotalExpensesAmt
PY Revenues Less Expenses-$9,896,147PYRevenuesLessExpensesAmt
CY Revenues Less Expenses$2,741,804CYRevenuesLessExpensesAmt
Total Assets BOY$90,551,380TotalAssetsBOYAmt
Total Assets EOY$96,561,632TotalAssetsEOYAmt
Total Liabilities BOY$9,811,073TotalLiabilitiesBOYAmt
Total Liabilities EOY$3,614,475TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY$80,740,307NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY$92,947,157NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part IIIYes (X)InfoInScheduleOPartIIIInd
MissionTHE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. SEE SCHEDULE O.THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER BY FUNDING SCIENTIFIC AND CLINICAL RESEARCH RELATED TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF PANCREATIC CANCER; PROVIDING RESEARCH INFORMATION AND CLINICAL SUPPORT SERVICES TO PATIENTS, CAREGIVERS AND INDIVIDUALS AT HIGH RISK; AND INCREASING PUBLIC AWARENESS AND HOPE FOR THOSE DEALING WITH THIS DISEASE.MissionDesc
Significant New Program Srvc0SignificantNewProgramSrvcInd
Significant Change0SignificantChangeInd
Expense$16,556,918ExpenseAmt
Grant$15,742,900GrantAmt
DescRESEARCH PROGRAM: THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER. TO ADVANCE PROGRESS TOWARD THIS GOAL, THE FOUNDATION COMMITTED AN ADDITIONAL $24 MILLION TO RESEARCH DURING FY2021, BRINGING THE CUMULATIVE TOTAL INVESTED THROUGH JUNE 2021 TO $225 MILLION. SEE SCHEDULE O.Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

FieldValueIRS element (for citing)
Expense$1,004,578ExpenseAmt
DescPUBLIC EDUCATION AND INFORMATION PROGRAM: THE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER BY FUNDING SCIENTIFIC AND CLINICAL RESEARCH RELATED TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF PANCREATIC CANCER; PROVIDING RESEARCH INFORMATION AND CLINICAL SUPPORT SERVICES TO PATIENTS, CAREGIVERS AND INDIVIDUALS AT HIGH RISK; AND INCREASING PUBLIC AWARENESS AND HOPE FOR THOSE DEALING WITH THIS DISEASE. SEE SCHEDULE O.PUBLIC EDUCATION AND INFORMATION PROGRAMTHE LUSTGARTEN FOUNDATION IS THE LARGEST PRIVATE FUNDER OF PANCREATIC CANCER RESEARCH IN THE WORLD. THE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER BY FUNDING SCIENTIFIC AND CLINICAL RESEARCH RELATED TO THE DIAGNOSIS, TREATMENT AND PREVENTION OF PANCREATIC CANCER; PROVIDING RESEARCH INFORMATION AND CLINICAL SUPPORT SERVICES TO PATIENTS, CAREGIVERS AND INDIVIDUALS AT HIGH RISK; AND INCREASING PUBLIC AWARENESS AND HOPE FOR THOSE DEALING WITH THIS DISEASE.THE LUSTGARTEN FOUNDATION CREATED, PRINTED AND DISTRIBUTED MATERIALS TO UPDATE PATIENTS, CAREGIVERS, SURVIVORS, DONORS, VOLUNTEERS, WALK AND EVENT LEADERS AND CORPORATE SPONSORS ON RESEARCH DEVELOPMENTS, FOUNDATION MILESTONES AND WALKS/EVENTS. MATERIALS INCLUDED: - LUSTGARTENLIVE! SERIES OF RESEARCH-FOCUSED, INTERACTIVE WEBINARS - PROGRESS & PROMISE NEWSLETTERS - ANNUAL REPORT - MONTHLY E-NEWSLETTER WITH VIDEO INTRODUCTION - RESEARCH MILESTONES UPDATE - INCREASED FOCUS ON VIDEO, INCLUDING A VIRTUAL TOUR OF THE LUSTGARTEN LAB AT COLD SPRING HARBOR LABORATORY - PRE-PACKAGED ARTICLE FOR PUBLICATION IN COMMUNITY NEWSPAPERS NATIONWIDE WITH ACCOMPANYING RADIO PUBLIC SERVICE ANNOUNCEMENT - TELEVISION PUBLIC SERVICE ANNOUNCEMENT FOCUSING ON THE FOUNDATION'S COMMITMENT TO RESEARCH - PANCREATIC CANCER COLLECTIVE RADIO AND DIGITAL PUBLIC SERVICE ANNOUNCEMENTS FOCUSED ON INCREASING DIVERSITY IN CLINICAL TRIALS.WE ALSO CONTINUE DISTRIBUTING OUR UNDERSTANDING PANCREATIC CANCER: A GUIDE FOR PATIENTS & CAREGIVERS HANDBOOK, CONTAINING INFORMATION ON NAVIGATING A PANCREATIC CANCER DIAGNOSIS AND TREATMENT. THE BOOK AND MANY OF THE MATERIALS NOTED ABOVE ARE ACCESSIBLE AT WWW.LUSTGARTEN.ORG.Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

FieldValueIRS element (for citing)
Expense$159,898ExpenseAmt
DescPROFESSIONAL EDUCATION PROGRAM: PROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH SCIENTISTS, DIRECTORS OF THE DEDICATED LABORATORIES AND COLLABORATING ORGANIZATIONS AS WELL AS ATTENDING/PRESENTING VIRTUALLY AT SCIENTIFIC MEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER. SEE SCHEDULE O.PROFESSIONAL EDUCATION PROGRAMPROFESSIONAL EDUCATION FOCUSED ON THE FOUNDATION'S SENIOR LEADERSHIP CONDUCTING HIGH-LEVEL MEETINGS WITH SCIENTISTS, DIRECTORS OF THE DEDICATED LABORATORIES AND COLLABORATING ORGANIZATIONS AS WELL AS ATTENDING/PRESENTING VIRTUALLY AT SCIENTIFIC MEETINGS FOR ORGANIZATIONS INCLUDING THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) AND STAND UP TO CANCER. THE FOUNDATION SERVED AS A LEAD SPONSOR FOR THE AACR SPECIAL MEETING ON PANCREATIC CANCER HELD VIA ZOOM IN SEPTEMBER 2021. THE FOUNDATION HELD ITS ANNUAL SCIENTIFIC MEETING FOR THE SCIENTIFIC ADVISORY BOARD AND SELECT RESEARCHERS VIA ZOOM IN NOVEMBER 2021 AS WELL. THESE MEETINGS HELP FOSTER COLLABORATION AND A BETTER UNDERSTANDING OF GLOBAL DEVELOPMENTS IN PANCREATIC CANCER RESEARCH AND PROGRESS/TRENDS TO HELP SHAPE THE FOUNDATION'S ANNUAL RESEARCH PROGRAM AND LONG-TERM STRATEGIC GOALS.Desc
FieldValueIRS element (for citing)
Total Program Service Expenses$17,721,394TotalProgramServiceExpensesAmt
Described In Section501c3Yes (1)DescribedInSection501c3Ind
Schedule B RequiredYes (1)ScheduleBRequiredInd
Political Campaign Acty0PoliticalCampaignActyInd
Lobbying Activities0LobbyingActivitiesInd
Subject To Proxy Tax0SubjectToProxyTaxInd
Donor Advised Fund0DonorAdvisedFundInd
Conservation Easements0ConservationEasementsInd
Collections Of Art0CollectionsOfArtInd
Credit Counseling0CreditCounselingInd
Donor Rstr Or Quasi Endowments0DonorRstrOrQuasiEndowmentsInd
Report Land Building EquipmentYes (1)ReportLandBuildingEquipmentInd
Report Investments Other Sec0ReportInvestmentsOtherSecInd
Report Program Related Invst0ReportProgramRelatedInvstInd
Report Other Assets0ReportOtherAssetsInd
Report Other LiabilitiesYes (1)ReportOtherLiabilitiesInd
Include FIN48 FootnoteYes (1)IncludeFIN48FootnoteInd
Independent Audit Fincl StmtYes (1)IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt0ConsolidatedAuditFinclStmtInd
School Operating0SchoolOperatingInd
Foreign Office0ForeignOfficeInd
Foreign ActivitiesYes (1)ForeignActivitiesInd
More Than5000 K To OrgYes (1)MoreThan5000KToOrgInd
More Than5000 K To Individuals0MoreThan5000KToIndividualsInd
Professional FundraisingYes (1)ProfessionalFundraisingInd
Fundraising ActivitiesYes (1)FundraisingActivitiesInd
Gaming Activities0GamingActivitiesInd
Operate Hospital0OperateHospitalInd
Grants To OrganizationsYes (1)GrantsToOrganizationsInd
Grants To Individuals0GrantsToIndividualsInd
Schedule J RequiredYes (1)ScheduleJRequiredInd
Tax Exempt Bonds0TaxExemptBondsInd
Engaged In Excess Benefit Trans0EngagedInExcessBenefitTransInd
PY Excess Benefit Trans0PYExcessBenefitTransInd
Loan Outstanding0LoanOutstandingInd
Grant To Related Person0GrantToRelatedPersonInd
Business Rln With Org Mem0BusinessRlnWithOrgMemInd
Business Rln With Fam Mem0BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent0BusinessRlnWith35CtrlEntInd
Deductible Non Cash ContriYes (1)DeductibleNonCashContriInd
Deductible Art Contribution0DeductibleArtContributionInd
Terminate Operations0TerminateOperationsInd
Partial Liquidation0PartialLiquidationInd
Disregarded Entity0DisregardedEntityInd
Related Entity0RelatedEntityInd
Related Organization Ctrl Ent0RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org0TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp0ActivitiesConductedPrtshpInd
Schedule O RequiredYes (1)ScheduleORequiredInd
IRP Document29IRPDocumentCnt
IRP Document W2 G0IRPDocumentW2GCnt
Backup Wthld ComplianceYes (1)BackupWthldComplianceInd
Employee25EmployeeCnt
Employment Tax Returns FiledYes (1)EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit0UnrelatedBusIncmOverLimitInd
Foreign Financial Account0ForeignFinancialAccountInd
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTransInd
Taxable Party Notification0TaxablePartyNotificationInd
Nondeductible Contributions0NondeductibleContributionsInd
Quid Pro Quo ContributionsYes (1)QuidProQuoContributionsInd
Quid Pro Quo Contri DisclYes (1)QuidProQuoContriDisclInd
Form8282 Property Disposed Of0Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct0RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct0PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services0IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt0SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc0SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VIYes (X)InfoInScheduleOPartVIInd
Governing Body Voting Members15GoverningBodyVotingMembersCnt
Independent Voting Member14IndependentVotingMemberCnt
Family Or Business RlnYes (1)FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties0DelegationOfMgmtDutiesInd
Change To Org Documents0ChangeToOrgDocumentsInd
Material Diversion Or Misuse0MaterialDiversionOrMisuseInd
Members Or Stockholders0MembersOrStockholdersInd
Election Of Board Members0ElectionOfBoardMembersInd
Decisions Subject To Approva0DecisionsSubjectToApprovaInd
Minutes Of Governing BodyYes (1)MinutesOfGoverningBodyInd
Minutes Of CommitteesYes (1)MinutesOfCommitteesInd
Officer Mailing Address0OfficerMailingAddressInd
Local Chapters0LocalChaptersInd
Form990 Provided To Gvrn BodyYes (1)Form990ProvidedToGvrnBodyInd
Conflict Of Interest PolicyYes (1)ConflictOfInterestPolicyInd
Annual Disclosure Covered PrsnYes (1)AnnualDisclosureCoveredPrsnInd
Regular Monitoring EnfrcYes (1)RegularMonitoringEnfrcInd
Whistleblower PolicyYes (1)WhistleblowerPolicyInd
Document Retention PolicyYes (1)DocumentRetentionPolicyInd
Compensation Process CEOYes (1)CompensationProcessCEOInd
Compensation Process OtherYes (1)CompensationProcessOtherInd
Investment In Joint Venture0InvestmentInJointVentureInd
States Where Copy Of Return Is FldALStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldARStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldCTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldFLStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldGAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldHIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldILStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKSStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldKYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMEStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMDStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMIStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldMOStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNVStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNJStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNMStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNYStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldNCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOHStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldOKStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldORStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldPAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldSCStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldTNStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldUTStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldVAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWAStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWVStatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is FldWIStatesWhereCopyOfReturnIsFldCd
Upon RequestYes (X)UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1FAISAL JAWAIDBusinessNameLine1Txt
FieldValueIRS element (for citing)
Phone5167371555PhoneNum

US Address USAddress

FieldValueIRS element (for citing)
Address Line1415 CROSSWAYS PARK DRIVE SUITE DAddressLine1Txt
CityWOODBURYCityNm
State AbbreviationNYStateAbbreviationCd
ZIP11797ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (22 entries)

TitleTitleTxtAverage Hours Per WeekAverageHoursPerWeekRtAverage Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRtIndividual Trustee Or DirectorIndividualTrusteeOrDirectorIndOfficerOfficerIndReportable Comp From OrgReportableCompFromOrgAmtReportable Comp From Rltd OrgReportableCompFromRltdOrgAmtOther CompensationOtherCompensationAmtHighest Compensated EmployeeHighestCompensatedEmployeeInd
ANDREW LUSTGARTEN
CHAIRMAN5.000.00Yes (X)Yes (X)$0$0$0
JAMES DOLAN
VICE CHAIRMAN2.000.00Yes (X)Yes (X)$0$0$0
ADAM SILVER
VICE CHAIRMAN2.000.00Yes (X)Yes (X)$0$0$0
CHARLES F DOLAN
CHAIRMAN EMERITUS2.000.00Yes (X)Yes (X)$0$0$0
ROBERT F VIZZA PHD
CHAIRMAN EMERITUS (END 5/9/2020)35.000.00Yes (X)$580,751$0$9,086
WILLIAM BELL
TREASURER2.000.00Yes (X)Yes (X)$0$0$0
JOHN H COBB
DIRECTOR2.000.00Yes (X)$0$0$0
JESSICA LUSTGARTEN COURTEMANCHE
DIRECTOR2.000.00Yes (X)$0$0$0
QUENTIN F DOLAN
TRUSTEE2.000.00Yes (X)$0$0$0
JENNIE FORTUNOFF
DIRECTOR2.000.00Yes (X)$0$0$0
KEN GOODMAN MD FACR
DIRECTOR2.000.00Yes (X)$0$0$0
MARCIA LUSTGARTEN
DIRECTOR2.000.00Yes (X)$0$0$0
SHEILA MAHONY
DIRECTOR2.000.00Yes (X)$0$0$0
CHARLES R SCHUELER
DIRECTOR2.000.00Yes (X)$0$0$0
WILLA SHALIT
DIRECTOR2.000.00Yes (X)$0$0$0
LINDA TANTAWI
CHIEF EXEC OFCR (START 12/1/20)40.000.00Yes (X)$24,334$0$2,726
KERRI KAPLAN
PRESIDENT, VP OF MAJOR GIFTS45.000.00Yes (X)$331,122$0$28,378
JOHANNA RICHMAN
CHIEF FIN OFCR (START 9/21/20)40.000.00Yes (X)$62,137$0$6,605
CATHERINE WEBER
VP DEVELOPMENT OPERATIONS40.000.00Yes (X)$195,829$0$30,404
STEPHANIE H ELSEA
VP MARKETING & COMMUNICATIONS40.000.00$187,756$0$18,812Yes (X)
ANDREW S RAKEMAN
VICE PRESIDENT OF RESEARCH40.000.00$158,491$0$32,179Yes (X)
JASON RICE
NATIONAL DIRECTOR OF EVENTS40.000.00$139,045$0$5,000Yes (X)
FieldValueIRS element (for citing)
Total Reportable Comp From Org$1,679,465TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org$0TotReportableCompRltdOrgAmt
Total Other Compensation$133,190TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K6IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed0FormerOfcrEmployeesListedInd
Total Comp Greater Than150 KYes (1)TotalCompGreaterThan150KInd
Compensation From Other Srcs0CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp

Contractor Name ContractorName

Business Name BusinessName

FieldValueIRS element (for citing)
Business Name Line1FAIRCOM NEW YORKBusinessNameLine1Txt

Contractor Address ContractorAddress

US Address USAddress

FieldValueIRS element (for citing)
Address Line112 WEST 27TH STREET 13TH FL SUITEAddressLine1Txt
CityNEW YORKCityNm
State AbbreviationNYStateAbbreviationCd
ZIP10001ZIPCd
FieldValueIRS element (for citing)
ServicesMARKETINGServicesDesc
Compensation$620,963CompensationAmt
FieldValueIRS element (for citing)
Cntrct Rcvd Greater Than100 K1CntrctRcvdGreaterThan100KCnt
Fundraising$3,378,483FundraisingAmt
All Other Contributions$12,283,125AllOtherContributionsAmt
Noncash Contributions$142,960NoncashContributionsAmt
Total Contributions$15,661,608TotalContributionsAmt

Investment Income InvestmentIncomeGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,890,317TotalRevenueColumnAmt
Exclusion$1,890,317ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$1,361,709TotalRevenueColumnAmt
Exclusion$1,361,709ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

FieldValueIRS element (for citing)
Securities$76,978,283SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

FieldValueIRS element (for citing)
Securities$71,224,359SecuritiesAmt

Gain Or Loss GainOrLossGrp

FieldValueIRS element (for citing)
Securities$5,753,924SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

FieldValueIRS element (for citing)
Total Revenue Column$5,753,924TotalRevenueColumnAmt
Exclusion$5,753,924ExclusionAmt
FieldValueIRS element (for citing)
Fundraising Gross Income$8,150FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event$3,378,483ContriRptFundraisingEventAmt
Fundraising Direct Expenses$207,875FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

FieldValueIRS element (for citing)
Total Revenue Column-$199,725TotalRevenueColumnAmt
Exclusion-$199,725ExclusionAmt

Total Revenue TotalRevenueGrp

FieldValueIRS element (for citing)
Total Revenue Column$24,467,833TotalRevenueColumnAmt
Related Or Exempt Func Income$0RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue$0UnrelatedBusinessRevenueAmt
Exclusion$8,806,225ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

FieldValueIRS element (for citing)
Total$15,342,948TotalAmt
Program Services$15,342,948ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

FieldValueIRS element (for citing)
Total$399,952TotalAmt
Program Services$399,952ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

FieldValueIRS element (for citing)
Total$989,673TotalAmt
Program Services$326,592ProgramServicesAmt
Management And General$257,315ManagementAndGeneralAmt
Fundraising$405,766FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

FieldValueIRS element (for citing)
Total$1,609,792TotalAmt
Program Services$531,231ProgramServicesAmt
Management And General$418,546ManagementAndGeneralAmt
Fundraising$660,015FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

FieldValueIRS element (for citing)
Total$50,661TotalAmt
Program Services$16,718ProgramServicesAmt
Management And General$13,172ManagementAndGeneralAmt
Fundraising$20,771FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

FieldValueIRS element (for citing)
Total$261,482TotalAmt
Program Services$86,290ProgramServicesAmt
Management And General$67,984ManagementAndGeneralAmt
Fundraising$107,208FundraisingAmt

Payroll Taxes PayrollTaxesGrp

FieldValueIRS element (for citing)
Total$118,577TotalAmt
Program Services$39,130ProgramServicesAmt
Management And General$30,830ManagementAndGeneralAmt
Fundraising$48,617FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total$697,612TotalAmt
Fundraising$697,612FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

FieldValueIRS element (for citing)
Total$286,230TotalAmt
Management And General$286,230ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

FieldValueIRS element (for citing)
Total$549,510TotalAmt
Program Services$263,555ProgramServicesAmt
Management And General$285,955ManagementAndGeneralAmt

Advertising AdvertisingGrp

FieldValueIRS element (for citing)
Total$205,648TotalAmt
Program Services$205,648ProgramServicesAmt

Office Expenses OfficeExpensesGrp

FieldValueIRS element (for citing)
Total$417,071TotalAmt
Program Services$146,756ProgramServicesAmt
Management And General$107,855ManagementAndGeneralAmt
Fundraising$162,460FundraisingAmt

Information Technology InformationTechnologyGrp

FieldValueIRS element (for citing)
Total$150,385TotalAmt
Program Services$110,283ProgramServicesAmt
Management And General$40,102ManagementAndGeneralAmt

Occupancy OccupancyGrp

FieldValueIRS element (for citing)
Total$236,153TotalAmt
Program Services$106,267ProgramServicesAmt
Management And General$35,425ManagementAndGeneralAmt
Fundraising$94,461FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

FieldValueIRS element (for citing)
Total$33,489TotalAmt
Fundraising$33,489FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

FieldValueIRS element (for citing)
Total$84,883TotalAmt
Program Services$37,348ProgramServicesAmt
Management And General$13,582ManagementAndGeneralAmt
Fundraising$33,953FundraisingAmt

Insurance InsuranceGrp

FieldValueIRS element (for citing)
Total$40,307TotalAmt
Program Services$17,956ProgramServicesAmt
Management And General$6,391ManagementAndGeneralAmt
Fundraising$15,960FundraisingAmt

Other Expenses OtherExpensesGrp (3 entries)

DescDescTotalTotalAmtManagement And GeneralManagementAndGeneralAmtFundraisingFundraisingAmtProgram ServicesProgramServicesAmt
BANK AND CREDIT CARD FE$150,711$10,808$139,903
RESEARCH SUPPORT$82,687$82,687
OTHER$18,258$2,923$7,302$8,033

Total Functional Expenses TotalFunctionalExpensesGrp

FieldValueIRS element (for citing)
Total$21,726,029TotalAmt
Program Services$17,721,394ProgramServicesAmt
Management And General$1,577,118ManagementAndGeneralAmt
Fundraising$2,427,517FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

FieldValueIRS element (for citing)
BOY$1,910,337BOYAmt
EOY$4,253,446EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

FieldValueIRS element (for citing)
BOY$318,852BOYAmt
EOY$515,050EOYAmt

Accounts Receivable AccountsReceivableGrp

FieldValueIRS element (for citing)
EOY$1,508,338EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

FieldValueIRS element (for citing)
BOY$174,487BOYAmt
EOY$190,633EOYAmt
FieldValueIRS element (for citing)
Land Bldg Equip Cost Or Other Bss$237,050LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec$105,420LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

FieldValueIRS element (for citing)
BOY$165,524BOYAmt
EOY$131,630EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

FieldValueIRS element (for citing)
BOY$87,982,180BOYAmt
EOY$89,962,535EOYAmt

Total Assets TotalAssetsGrp

FieldValueIRS element (for citing)
BOY$90,551,380BOYAmt
EOY$96,561,632EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

FieldValueIRS element (for citing)
BOY$478,590BOYAmt
EOY$533,611EOYAmt

Grants Payable GrantsPayableGrp

FieldValueIRS element (for citing)
BOY$8,774,834BOYAmt
EOY$2,997,905EOYAmt

Deferred Revenue DeferredRevenueGrp

FieldValueIRS element (for citing)
BOY$480,772BOYAmt

Other Liabilities OtherLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$76,877BOYAmt
EOY$82,959EOYAmt

Total Liabilities TotalLiabilitiesGrp

FieldValueIRS element (for citing)
BOY$9,811,073BOYAmt
EOY$3,614,475EOYAmt
FieldValueIRS element (for citing)
Organization Follows FASB117Yes (X)OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$80,376,307BOYAmt
EOY$92,560,157EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

FieldValueIRS element (for citing)
BOY$364,000BOYAmt
EOY$387,000EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$80,740,307BOYAmt
EOY$92,947,157EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

FieldValueIRS element (for citing)
BOY$90,551,380BOYAmt
EOY$96,561,632EOYAmt
FieldValueIRS element (for citing)
Reconcilation Revenue Expnss$2,741,804ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst$9,465,046NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets$0OtherChangesInNetAssetsAmt
Method Of Accounting AccrualYes (X)MethodOfAccountingAccrualInd
Accountant Compile Or Review0AccountantCompileOrReviewInd
FS AuditedYes (1)FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

FieldValueIRS element (for citing)
Separate Basis Fincl StmtYes (X)SeparateBasisFinclStmtInd
FieldValueIRS element (for citing)
Audit CommitteeYes (1)AuditCommitteeInd
Federal Grant Audit Required0FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Public Organization170Yes (X)PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$43,176,330CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$12,048,978CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$15,969,356CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$13,046,433CurrentTaxYearMinus1YearAmt
Current Tax Year$15,661,608CurrentTaxYearAmt
Total$99,902,705TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$43,176,330CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$12,048,978CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$15,969,356CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$13,046,433CurrentTaxYearMinus1YearAmt
Current Tax Year$15,661,608CurrentTaxYearAmt
Total$99,902,705TotalAmt
FieldValueIRS element (for citing)
Substantial Contributors Tot$38,962,370SubstantialContributorsTotAmt
Public Support Total170$60,940,335PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$1,377,642CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$515,595CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$1,755,392CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$2,417,283CurrentTaxYearMinus1YearAmt
Current Tax Year$3,252,026CurrentTaxYearAmt
Total$9,317,938TotalAmt

Other Income170 OtherIncome170Grp

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years$349,626CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years$99,169CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years$371,093CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year$219,523CurrentTaxYearMinus1YearAmt
Current Tax Year$8,150CurrentTaxYearAmt
Total$1,047,561TotalAmt
FieldValueIRS element (for citing)
Total Support$110,268,204TotalSupportAmt
Public Support CY1700.55270PublicSupportCY170Pct
Public Support PY1700.52850PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170Yes (X)ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE A, PART IIFormAndLineReferenceDesc
ExplanationTHE FOUNDATION CHANGED ITS FISCAL YEAR END DATE TO JUNE 30TH IN 2018, RESULTING IN A SHORT PERIOD TAX YEAR OF SIX MONTHS FROM JANUARY 1 - JUNE 30, 2018. AS A RESULT, AMOUNTS REPORTED IN COLUMN (B) REFLECT AMOUNTS FOR THE SHORT PERIOD JANUARY 1, 2018 - JUNE 30, 2018. COLUMN (A) REFLECTS AMOUNTS REPORTED FOR CALENDAR YEAR 2017. AMOUNTS ON LINE 10 REPRESENT GROSS INCOME FROM FUNDRAISING EVENTS.ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

FieldValueIRS element (for citing)
ContributorRESTRICTEDContributorNum

Contributor Business Name ContributorBusinessName

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor US Address ContributorUSAddress

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Total ContributionsRESTRICTEDTotalContributionsAmt

Schedule D IRS990ScheduleD

Leasehold Improvements LeaseholdImprovementsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$5,865OtherCostOrOtherBasisAmt
Depreciation$3,603DepreciationAmt
Book Value$2,262BookValueAmt

Equipment EquipmentGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$18,631OtherCostOrOtherBasisAmt
Depreciation$6,175DepreciationAmt
Book Value$12,456BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

FieldValueIRS element (for citing)
Other Cost Or Other Basis$212,554OtherCostOrOtherBasisAmt
Depreciation$95,642DepreciationAmt
Book Value$116,912BookValueAmt
FieldValueIRS element (for citing)
Total Book Value Land Buildings$131,630TotalBookValueLandBuildingsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp

FieldValueIRS element (for citing)
DescDEFERRED RENT OBLIGATIONDesc
Amt$82,959Amt
FieldValueIRS element (for citing)
Total Liability$82,959TotalLiabilityAmt
Footnote TextYes (X)FootnoteTextInd
Total Rev Etc Audited Fincl Stmt$38,277,396TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst$9,465,046NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts$4,630,747DonatedServicesAndUseFcltsAmt
Revenue Not Reported$14,095,793RevenueNotReportedAmt
Revenue Subtotal$24,181,603RevenueSubtotalAmt
Investment Expenses Not Incld$286,230InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt$286,230RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990$24,467,833TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt$26,070,546TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts$4,630,747DonatedServicesUseFcltsAmt
Expenses Not Reported$4,630,747ExpensesNotReportedAmt
Expenses Subtotal$21,439,799ExpensesSubtotalAmt
Investment Expenses Not Incld2$286,230InvestmentExpensesNotIncld2Amt
Expenses Not Rpt Fincl Stmt$286,230ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990$21,726,029TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART X, LINE 2:FormAndLineReferenceDesc
ExplanationTHE FOUNDATION HAS RECEIVED A FINAL DETERMINATION LETTER FROM THE INTERNAL REVENUE SERVICE STATING THAT THE FOUNDATION IS EXEMPT FROM FEDERAL INCOME TAX UNDER SECTION 501(C)(3). THE FOUNDATION IS TREATED AS A PUBLIC CHARITY AS DEFINED IN SECTIONS 509(A)(1) AND 170(B)(1)(A)(VI). THE FOUNDATION FOLLOWS THE PROVISIONS OF ACCOUNTING STANDARDS CODIFICATION (ASC) SUBTOPIC 740-10, INCOME TAXES - OVERALL (ASC 740-10), RELATING TO UNCERTAINTY IN INCOME TAXES. FOR THE FOUNDATION, ASC 740-10 IS PRIMARILY APPLICABLE TO THE INCURRENCE OF UNRELATED BUSINESS INCOME TAX ATTRIBUTABLE TO CERTAIN OF ITS INVESTMENTS. ASC 740-10 ESTABLISHES A MINIMUM THRESHOLD FOR FINANCIAL STATEMENT RECOGNITION OF THE BENEFITS OF POSITIONS TAKEN, OR EXPECTED TO BE TAKEN, IN FILING TAX RETURNS. IT REQUIRES THE EVALUATION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN, IN THE COURSE OF PREPARING THE FOUNDATION'S INCOME TAX RETURNS TO DETERMINE WHETHER THE TAX POSITIONS ARE "MORE LIKELY THAN NOT" OF BEING SUSTAINED BY THE APPLICABLE TAX AUTHORITY. TAX POSITIONS NOT DEEMED TO MEET THE MORE-LIKELY THAN-NOT THRESHOLD ARE RECORDED AS TAX EXPENSE. FOR THE YEARS ENDED JUNE 30, 2021 AND 2020, THE FOUNDATION HAS NOT IDENTIFIED OR PROVIDED FOR ANY SUCH POSITIONS.ExplanationTxt

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (2 entries)

RegionRegionTxtOfficesOfficesCntEmployeeEmployeeCntType Of Activities ConductedTypeOfActivitiesConductedTxtSpecific Services ProvidedSpecificServicesProvidedTxtRegion Total ExpendituresRegionTotalExpendituresAmt
EUROPE (INCLUDING ICELAND & GREENLAND)00GRANTMAKINGPANCREATIC CANCER RESEARCH$200,000
NORTH AMERICA00GRANTMAKINGPANCREATIC CANCER RESEARCH$199,952
FieldValueIRS element (for citing)
Subtotal Offices0SubtotalOfficesCnt
Subtotal Employees0SubtotalEmployeesCnt
Continuation Total Office0ContinuationTotalOfficeCnt
Continuation Total Employee0ContinuationTotalEmployeeCnt
Total Office0TotalOfficeCnt
Total Employee0TotalEmployeeCnt
Subtotal Spent$399,952SubtotalSpentAmt
Continuation Spent$0ContinuationSpentAmt
Total Spent$399,952TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (2 entries)

RegionRegionTxtPurpose Of GrantPurposeOfGrantTxtCash GrantCashGrantAmtManner Of Cash DisbursementMannerOfCashDisbursementTxt
EUROPE (INCLUDING ICELAND & GREENLAND)PANCREATIC CANCER RESEARCH$200,000WIRE/EFT
NORTH AMERICAPANCREATIC CANCER RESEARCH$199,952WIRE/EFT
FieldValueIRS element (for citing)
Total501c3 Org2Total501c3OrgCnt
Total Other Org0TotalOtherOrgCnt
Transfer To Foreign Corp0TransferToForeignCorpInd
Interest In Foreign Trust0InterestInForeignTrustInd
Foreign Corp Ownership0ForeignCorpOwnershipInd
Passive Foreign Investmest Co0PassiveForeignInvestmestCoInd
Foreign Partnership0ForeignPartnershipInd
Boycott Countries0BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
PART III ACCOUNTING METHOD:
SCHEDULE F, PART I, LINE 2GRANT MONITORING PROCESS THE ORGANIZATION REQUIRES ALL GRANTEES TO PROVIDE DETAILED REPORTING ON THEIR RESEARCH. THAT REPORTING INCLUDES ACCOUNTING FOR ALL FUNDS AND SHALL BE ACCOMPANIED BY ELECTRONIC COPIES OF ALL ARTICLES, IRRESPECTIVE OF WHETHER THEY WERE PUBLISHED, PRESENTED OR OTHERWISE DISCLOSED, CONCERNING GRANT RESEARCH WRITTEN BY THE PRINCIPAL INVESTIGATOR. FINAL GRANT ACCOUNTING IS DUE FROM THE SPONSORING INSTITUTION AND THE INSTITUTIONS AGREE TO REFUND ANY PORTION OF THE GRANT FUNDS TO THE FOUNDATION THAT WAS NOT USED FOR THE SPECIFIED PURPOSES DESCRIBED HEREIN AND RETURN TO THE FOUNDATION ANY UNEXPENDED FUNDS WITHIN THIRTY (30) DAYS AFTER THE EXPIRATION OR TERMINATION OF THE GRANT TERM, OR, AT THE FOUNDATION'S OPTION, THE FOUNDATION MAY, BY WRITTEN NOTICE, ALLOW THE SPONSORING INSTITUTION TO USE ANY REMAINING GRANT FUNDS IN FURTHERANCE OF GRANT RESEARCH IN PROGRESS AT THE TIME OF SUCH EXPIRATION. THE FOUNDATION SHALL HAVE THE RIGHT TO AUDIT THE USE OF GRANT FUNDS.

Schedule G IRS990ScheduleG

FieldValueIRS element (for citing)
Mail SolicitationsYes (X)MailSolicitationsInd
Email SolicitationsYes (X)EmailSolicitationsInd
In Person SolicitationsYes (X)InPersonSolicitationsInd
Solicitation Of Non Govt GrantsYes (X)SolicitationOfNonGovtGrantsInd
Special Fundraising EventsYes (X)SpecialFundraisingEventsInd
Agrmt Prof Fundraising ActyYes (1)AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (3 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdActivityActivityTxtFundraiser Control Of FundsFundraiserControlOfFundsIndGross ReceiptsGrossReceiptsAmtRetained By ContractorRetainedByContractorAmtNet To OrganizationNetToOrganizationAmt
FAIRCOM NEW YORK
12 WEST 27TH STNEW YORKNY10001DIRECT MAIL & MARKETING0$1,029,210$620,963$408,247
BUCKLEY EVENTS
17 MARBLE AVE 19PLEASANTVILLENY10570EVENT CONSULTING0$532,800$4,557$528,243
JC GREEVER INC
11 RIVERSIDE DR 2 EWNEW YORKNY10023DONOR MANAGEMENT0$85,000$72,092$12,908
FieldValueIRS element (for citing)
Total Gross Receipts$1,647,010TotalGrossReceiptsAmt
Total Retained By Contractors$697,612TotalRetainedByContractorsAmt
Total Net To Organization$949,398TotalNetToOrganizationAmt
Licensed StatesALLicensedStatesCd
Licensed StatesARLicensedStatesCd
Licensed StatesCALicensedStatesCd
Licensed StatesCOLicensedStatesCd
Licensed StatesCTLicensedStatesCd
Licensed StatesFLLicensedStatesCd
Licensed StatesGALicensedStatesCd
Licensed StatesHILicensedStatesCd
Licensed StatesILLicensedStatesCd
Licensed StatesKSLicensedStatesCd
Licensed StatesKYLicensedStatesCd
Licensed StatesMELicensedStatesCd
Licensed StatesMDLicensedStatesCd
Licensed StatesMALicensedStatesCd
Licensed StatesMILicensedStatesCd
Licensed StatesMNLicensedStatesCd
Licensed StatesMOLicensedStatesCd
Licensed StatesNVLicensedStatesCd
Licensed StatesNHLicensedStatesCd
Licensed StatesNJLicensedStatesCd
Licensed StatesNMLicensedStatesCd
Licensed StatesNYLicensedStatesCd
Licensed StatesNCLicensedStatesCd
Licensed StatesOHLicensedStatesCd
Licensed StatesOKLicensedStatesCd
Licensed StatesORLicensedStatesCd
Licensed StatesPALicensedStatesCd
Licensed StatesSCLicensedStatesCd
Licensed StatesTNLicensedStatesCd
Licensed StatesUTLicensedStatesCd
Licensed StatesVALicensedStatesCd
Licensed StatesWALicensedStatesCd
Licensed StatesWVLicensedStatesCd
Licensed StatesWILicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

FieldValueIRS element (for citing)
Event1SPRING GALAEvent1Nm
Gross Receipts Event1$532,800GrossReceiptsEvent1Amt
Charitable Contri Event1$532,800CharitableContriEvent1Amt
Food And Beverage Event1$309FoodAndBeverageEvent1Amt
Other Direct Expenses Event1$5,715OtherDirectExpensesEvent1Amt
Event2HOLIDAY BASHEvent2Nm
Gross Receipts Event2$172,606GrossReceiptsEvent2Amt
Charitable Contri Event2$167,606CharitableContriEvent2Amt
Gross Revenue Event2$5,000GrossRevenueEvent2Amt
Food And Beverage Event2$47FoodAndBeverageEvent2Amt
Entertainment Event2$700EntertainmentEvent2Amt
Other Direct Expenses Event2$9,840OtherDirectExpensesEvent2Amt
Other Events Total57OtherEventsTotalCnt
Gross Receipts Other Events$2,681,227GrossReceiptsOtherEventsAmt
Charitable Contri Other Events$2,678,077CharitableContriOtherEventsAmt
Gross Revenue Other Events$3,150GrossRevenueOtherEventsAmt
Entertainment Other Events$111EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events$191,153OthDirectExpnssOtherEventsAmt
Gross Receipts Total$3,386,633GrossReceiptsTotalAmt
Charitable Contributions Tot$3,378,483CharitableContributionsTotAmt
Gross Revenue Total Events$8,150GrossRevenueTotalEventsAmt
Food And Beverage Total Events$356FoodAndBeverageTotalEventsAmt
Entertainment Total Events$811EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events$206,708OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events$207,875DirectExpenseSummaryEventsAmt
Net Income Summary-$199,725NetIncomeSummaryAmt

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Grant Records MaintainedYes (1)GrantRecordsMaintainedInd

Recipient Table RecipientTable (16 entries)

Address Line1USAddress/AddressLine1TxtCityUSAddress/CityNmState AbbreviationUSAddress/StateAbbreviationCdZIPUSAddress/ZIPCdRecipient EINRecipientEINIRC SectionIRCSectionDescCash GrantCashGrantAmtPurpose Of GrantPurposeOfGrantTxtAddress Line2USAddress/AddressLine2Txt
AMERICAN ASSOCIATION FOR CANCER RESEARCH
615 CHESTNUT STPHILADELPHIAPA191064404236251648501(C)(3)$220,000PANCREATIC CANCER RESEARCH
CHILDREN'S HOSPITAL CORPORATION
300 LONGWOOD AVENUEBOSTONMA02115431987409501(C)(3)$30,000PANCREATIC CANCER RESEARCH
COLD SPRING HARBOR LABORATORY
ONE BUNGTOWN RDCOLD SPRING HBRNY11724112013303501(C)(3)$1,032,223PANCREATIC CANCER RESEARCH
THE TRUSTEES OF COLUMBIA UNIV IN THE CITY
615 W 13TH ST MC 8741NEW YORKNY10027135598093501(C)(3)$421,735PANCREATIC CANCER RESEARCH
DANA FARBER CANCER INSTITUTE
450 BROOKLINE AVENUENEW YORKNY02215042263040501(C)(3)$1,491,911PANCREATIC CANCER RESEARCH
HENRY FORD HEALTH SYSTEM
1 FORD PLACE RESEARCH ADMINISTRATIODETRIOTMI48202381357020501(C)(3)$75,000PANCREATIC CANCER RESEARCH2F
JOHNS HOPKINS UNIVERSITY
1650 ORLEANS STREETBALTIMORENY21287520595110501(C)(3)$2,222,732PANCREATIC CANCER RESEARCH
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
77 MASSACHUSETTS AVENUECAMBRIDGEMA02139042103594501(C)(3)$656,821PANCREATIC CANCER RESEARCH
NEW YORK UNIVERSITY
ONE PARK AVE 6TH FLNEW YORKNY10016135562308501(C)(3)$200,000PANCREATIC CANCER RESEARCH
OREGON HEALTH & SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK RD MAILPORTLANDOR97239931176109GOV'T$99,154PANCREATIC CANCER RESEARCHCODEL106
THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
10010 N TORREY PINES RDLA JOLLACA92037952160097501(C)(3)$500,000PANCREATIC CANCER RESEARCH
STAND UP TO CANCER - ENTERTAINMENT IND FDN
10880 WILSHIRE BLVD STE 1400LOS ANGELESCA90024951644609501(C)(3)$7,563,373PANCREATIC CANCER RESEARCH
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO
9500 GILAN DRIVE DEPT 0924LA JOLLACA92093956006144501(C)(3)$200,000PANCREATIC CANCER RESEARCH
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
3451 WALNUT STREET ROOM P221PHILADELPHIAPA19104231352685501(C)(3)$200,000PANCREATIC CANCER RESEARCHFRANKLIN BUILDING
WHITEHEAD INST FOR BIOMEDICAL RESEARCH
9 CAMBRIDGE CENTERCAMBRIDGEMA02142061043412501(C)(3)$230,000PANCREATIC CANCER RESEARCH
YALE UNIVERSITY
25 SCIENCE PARK 3RD FLNEW HAVENCT06520060646973501(C)(3)$200,000PANCREATIC CANCER RESEARCH
FieldValueIRS element (for citing)
Total501c3 Org16Total501c3OrgCnt

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, LINE 2:FormAndLineReferenceDesc
ExplanationTHE FOUNDATION MAKES GRANTS TO 501(C)(3) PUBLIC CHARITIES CONDUCTING PANCREATIC CANCER RESEARCH. AS PART OF THE REQUIREMENT FOR RECEIVING SUCH GRANTS, THE FOUNDATION REQUIRES PERIODIC UPDATES AND REPORTING ON SCIENTIFIC PROGRESS AND FINANCIAL EXPENDITURES.ExplanationTxt

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Form990 Of Other OrganizationsYes (X)Form990OfOtherOrganizationsInd
Compensation SurveyYes (X)CompensationSurveyInd
Board Or Committee ApprovalYes (X)BoardOrCommitteeApprovalInd
Severance PaymentYes (1)SeverancePaymentInd
Supplemental Nonqual Rtr Plan0SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm0EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org0CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs0CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org0CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs0CompBsdNetEarnsRltdOrgsInd
Any Non Fixed PaymentsYes (1)AnyNonFixedPaymentsInd
Initial Contract Exception0InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (5 entries)

TitleTitleTxtBase Compensation Filing OrgBaseCompensationFilingOrgAmtCompensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmtBonus Filing OrganizationBonusFilingOrganizationAmountBonus Related OrganizationsBonusRelatedOrganizationsAmtOther Compensation Filing OrgOtherCompensationFilingOrgAmtOther Compensation Rltd OrgsOtherCompensationRltdOrgsAmtDeferred Compensation Flng OrgDeferredCompensationFlngOrgAmtDeferred Comp Rltd OrgsDeferredCompRltdOrgsAmtNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmtNontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmtTotal Compensation Filing OrgTotalCompensationFilingOrgAmtTotal Compensation Rltd OrgsTotalCompensationRltdOrgsAmtComp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmtComp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
ROBERT F VIZZA PHD
CHAIRMAN EMERITUS (END 5/9/2020)$136,313$0$70,296$0$374,142$0$0$0$9,086$0$589,837$0$0$0
KERRI KAPLAN
PRESIDENT, VP OF MAJOR GIFTS$260,723$0$67,855$0$2,544$0$0$0$28,378$0$359,500$0$0$0
CATHERINE WEBER
VP DEVELOPMENT OPERATIONS$164,629$0$31,200$0$0$0$6,782$0$23,622$0$226,233$0$0$0
STEPHANIE H ELSEA
VP MARKETING & COMMUNICATIONS$169,428$0$17,500$0$828$0$7,000$0$11,812$0$206,568$0$0$0
ANDREW S RAKEMAN
VICE PRESIDENT OF RESEARCH$150,095$0$8,063$0$333$0$6,285$0$25,894$0$190,670$0$0$0

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferencePART I, LINE 4AFormAndLineReferenceDesc
ExplanationSEVERANCE COMPENSATION SCHEDULE J, PART I, LINE 4A ROBERT F. VIZZA RECEIVED SEVERANCE COMPENSATION OF $315,180 IN CALENDAR YEAR 2020. NONFIXED PAYMENTS SCHEDULE J, PART I, LINE 7 IN 2020, OFFICERS AND EMPLOYEES RECEIVED NONFIXED DISCRETIONARY BONUSES AS REPORTED ON SCHEDULE J, PART II, COLUMN (B)(II).ExplanationTxt

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

FieldValueIRS element (for citing)
Non Cash CheckboxYes (X)NonCashCheckboxInd
Contribution33ContributionCnt
Noncash Contributions Rpt F990$142,960NoncashContributionsRptF990Amt
Method Of Determining RevenuesAVG MKT VALUEMethodOfDeterminingRevenuesTxt
FieldValueIRS element (for citing)
Any Property That Must Be Held0AnyPropertyThatMustBeHeldInd
Review Process Unusual NC GiftsYes (1)ReviewProcessUnusualNCGiftsInd
Third Parties Used0ThirdPartiesUsedInd

Supplemental Information Detail SupplementalInformationDetail

FieldValueIRS element (for citing)
Form And Line ReferenceSCHEDULE M, PART I, COLUMN (B)FormAndLineReferenceDesc
ExplanationTHE AMOUNT IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS.ExplanationTxt

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (7 entries)

Form And Line ReferenceFormAndLineReferenceDescExplanationExplanationTxt
FORM 990, PART III, LINE 4ATHE FOUNDATION'S MISSION IS TO CURE PANCREATIC CANCER. TO ADVANCE PROGRESS TOWARD THIS GOAL, THE FOUNDATION COMMITTED AN ADDITIONAL $24 MILLION TO RESEARCH DURING FY2021, BRINGING THE CUMULATIVE TOTAL INVESTED THROUGH JUNE 2021 TO $225 MILLION. BECAUSE RESEARCH IS FUNDAMENTAL AND PROGRESS IS PARAMOUNT, THE FOUNDATION HAS SUPPORTED MORE THAN 300 PROJECTS WORLDWIDE, WITH PARTNERSHIPS AT NEARLY 70 ACADEMIC INSTITUTIONS. ADDITIONALLY, THE FOUNDATION PROVIDES TWO-THIRDS OF THE WORLD'S PRIVATE FUNDING FOR PANCREATIC CANCER RESEARCH FROM ORGANIZATIONS FOCUSED SOLELY ON THIS DISEASE. DURING FY2021, MAJOR LUSTGARTEN-FUNDED RESEARCH MILESTONES AND ACHIEVEMENTS HAVE FOCUSED ON: STRETCHING THE BOUNDARIES OF SCIENCE THROUGH CLINICAL TRIALS: THE FOUNDATION ESTABLISHED THE CLINICAL ACCELERATOR INITIATIVE (CAI) TO SHORTEN THE TIME FROM CLINICAL TRIAL CONCEPT TO LAUNCH USING A LUSTGARTEN-DEVELOPED PROCESS BASED ON THE BEST AVAILABLE SCIENCE AND EMPLOYING CUTTING-EDGE BIOMARKERS. THESE "SMARTER" CLINICAL TRIALS WILL GENERATE LARGE VOLUMES OF DATA THAT SCIENTISTS CAN USE NOW AND, IN THE FUTURE, TO INFORM AND IMPROVE CLINICAL TRIALS AND EXPEDITE NEW TREATMENTS. IN 2021, THE FOUNDATION APPROVED $6.1 MILLION TO FUND FOUR CAI STUDIES. THREE OF THESE CLINICAL STUDIES TEST IMMUNOTHERAPY TREATMENTS - LOOKING INTO WAYS THE BODY'S OWN IMMUNE SYSTEM CAN WORK TO COMBAT PANCREATIC CANCER SO MORE PATIENTS HAVE BETTER OUTCOMES. TWO STUDIES, ONE FOR METASTATIC PATIENTS AND ONE FOR PATIENTS IN THE NEOADJUVANT (PRE-SURGERY) SETTING, EXAMINE NEW COMBINATIONS OF VACCINES AND DRUGS TARGETING THE IMMUNE SYSTEM TO DETERMINE IF THEY CAN PREVENT TUMORS FROM BECOMING RESISTANT TO IMMUNE THERAPIES. THE THIRD STUDY TESTS A NEW COMBINATION OF DRUGS TO SIMULTANEOUSLY ACTIVATE THE T CELLS AND BLOCK THE INHIBITORY SIGNALS FROM THE TUMOR. THE TRANSLATIONAL ADVISORY GROUP, LED BY CHIEF MEDICAL ADVISOR DR. ELIZABETH JAFFEE AND COMPRISED OF RENOWNED PANCREATIC CANCER EXPERTS, GUIDES THE CAI BY IDENTIFYING, REVIEWING AND DEVELOPING THE BEST TRANSLATIONAL PROJECTS TO IMPACT PATIENT CARE IN THE CLINIC. THE TRANSLATIONAL ADVISORY GROUP IS BUILDING A NETWORK OF SITES TO EXECUTE THE PROPOSED RESEARCH IN SMALL CLINICAL TRIALS OF 10-20 PATIENTS EACH. THESE SCIENCE-DRIVEN STUDIES COULD DRAMATICALLY INFORM RESEARCH, ENABLING INVESTIGATORS TO QUICKLY DETERMINE IF PATIENTS ARE RESPONDING TO SPECIFIC TREATMENT APPROACHES AND WHY - INFORMATION THAT WILL HELP ENHANCE CLINICAL TRIALS AND ULTIMATELY, CLINICAL CARE. ACCELERATING THE PACE OF DISCOVERY AT THE DEDICATED LUSTGARTEN LABS: THE LUSTGARTEN FOUNDATION IS THE ONLY NON-PROFIT TO FUND FIVE DEDICATED PANCREATIC CANCER RESEARCH LABS. THESE LABS ARE UNITED IN THEIR SHARED GOALS OF INCREASING COLLABORATION BETWEEN WORLD-RENOWNED PANCREATIC CANCER RESEARCHERS, EXPLORING PROMISING AVENUES FOR UNDERSTANDING AND TREATING PANCREATIC CANCER AND IMPROVING PATIENT OUTCOMES. - COLD SPRING HARBOR LABORATORY (LONG ISLAND, NEW YORK) FOCUSING ON PERSONALIZED MEDICINE DR. DAVID TUVESON LEADS THE LUSTGARTEN LABORATORY AT COLD SPRING HARBOR LABORATORY, DESIGNING NEW MODELS OF THE DISEASE AND DISCOVERING NOVEL THERAPEUTIC AND DIAGNOSTIC PLATFORMS TO BRING NEW OPTIONS TO PATIENTS MORE RAPIDLY. DR. TUVESON WAS THE FIRST SCIENTIST TO DEVELOP A PANCREATIC CANCER ORGANOID - A THREE-DIMENSIONAL CELL CULTURE SYSTEM WHICH REPRODUCES A PATIENT'S TUMOR. THIS ENABLES RESEARCHERS TO REPEATEDLY TEST THE EFFECTIVENESS OF DIFFERENT DRUGS TO ACCURATELY PREDICT HOW A PATIENT WILL RESPOND TO VARIOUS THERAPIES, OFFERING THE HOPE OF PERSONALIZED CANCER TREATMENTS. IN ADDITION TO OTHER PROJECTS, THE LAB'S ORGANOID FACILITY IS GROWING AND TESTING ORGANOIDS FOR THE ONGOING PASS-01 CLINICAL TRIAL. - DANA-FARBER CANCER INSTITUTE (BOSTON, MASSACHUSETTS) ADVANCING TRANSLATIONAL RESEARCH UNDER THE LEADERSHIP OF DR. BRIAN WOLPIN, THE LUSTGARTEN LABORATORY AT DANA-FARBER IS A CRITICAL HUB FOR ADVANCING RESEARCH FROM THE LABORATORY TO THE CLINIC, INITIATING SCIENTIFICALLY-DRIVEN CLINICAL TRIALS AND IDENTIFYING NEW APPROACHES TO EARLY DETECTION. DR. WOLPIN AND HIS TEAM ARE ALSO ANALYZING PANCREATIC CANCER SUBTYPES TO UNDERSTAND MECHANISMS OF DRUG RESISTANCE AND THE GENETIC DRIVERS THAT DETERMINE EACH SUBTYPE. DURING FY2021, DR. WOLPIN AND HIS TEAM BEGAN STUDYING A POTENTIAL PROCESS TO "RE-AWAKEN" T CELLS (AN IMMUNE SYSTEM CELL) THAT PENETRATE THE PANCREATIC TUMORS BUT ARE RENDERED "EXHAUSTED AND INEFFECTIVE BY TUMOR SIGNALS. THE CLINICAL STUDY WILL TEST A NEW COMBINATION OF DRUGS DESIGNED TO SIMULTANEOUSLY ACTIVATE THE T CELLS AND BLOCK THE INHIBITORY SIGNALS FROM THE TUMOR. - JOHNS HOPKINS (BALTIMORE, MARYLAND) FURTHERING EARLY DETECTION AND THERAPEUTICS DIRECTED BY DR. BERT VOGELSTEIN, THE LUSTGARTEN LABORATORY AT JOHNS HOPKINS IS USING ITS EXPERTISE IN EARLY DETECTION TO DISCOVER PANCREATIC CANCER AT AN EARLIER STAGE, WHEN PATIENTS MAY BE SURGICAL CANDIDATES, AND IS DEVELOPING NEW THERAPEUTIC APPROACHES BASED ON GENETIC ALTERATIONS. IN 2021, EXACT SCIENCES ACQUIRED THE RIGHTS TO CANCERSEEK, A POWERFUL BLOOD TEST CAPABLE OF DETECTING THE EARLY PRESENCE OF MULTIPLE CANCERS AND DEVELOPED AT THE JOHNS HOPKINS LAB. (PLEASE SEE EARLY DETECTION SECTION WITHIN THIS DOCUMENT FOR MORE INFORMATION ON EARLY DETECTION ADVANCEMENTS.) - JOHNS HOPKINS (BALTIMORE, MARYLAND) ADVANCING IMMUNOLOGY LED BY DR. ELIZABETH JAFFEE, THIS LAB IS WORKING TO BRING NOVEL THERAPIES FOR PANCREATIC CANCER TO THE CLINIC AS QUICKLY AS POSSIBLE. BUILDING ON DECADES OF EXPERIENCE AND EXPERTISE IN THE IMMUNOLOGY OF PANCREATIC CANCER, DR. JAFFEE AND HER TEAM ARE FOCUSING ON IMMUNE THERAPIES AND DEVELOPING APPROACHES TO BRING THE BENEFITS OF THIS REVOLUTIONARY APPROACH TO TREATING TUMORS TO PANCREATIC CANCER. - MASSACHUSETTS INSTITUTE OF TECHNOLOGY (CAMBRIDGE, MASSACHUSETTS) MERGING TECHNOLOGY AND ENGINEERING THE LUSTGARTEN LABORATORY AT MIT IS LEVERAGING ITS UNPARALLELED EXPERTISE IN CANCER BIOLOGY AND ENGINEERING TO ADVANCE PANCREATIC CANCER RESEARCH. LED BY DR. TYLER JACKS, THE LABORATORY IS STUDYING THE GENETIC EVENTS CONTRIBUTING TO CANCER DEVELOPMENT AND EXAMINING THE IMMUNE RESPONSES TO THE DISEASE USING MOLECULAR PROFILING TO IDENTIFY TUMOR MUTATIONS. DR. JACKS AND HIS TEAM ALSO ARE RUNNING PRECLINICAL TRIALS IN MOUSE MODEL SYSTEMS TO SEE WHICH DRUGS AND DRUG COMBINATIONS WORK BEST TO BRING ABOUT A PROPER IMMUNE RESPONSE AGAINST PANCREATIC CANCER. PURSUING EARLY DETECTION TECHNIQUES: - CANCERSEEK ACCELERATES EARLY DETECTION LUSTGARTEN-FUNDED RESEARCH AT JOHNS HOPKINS PLAYED AN INSTRUMENTAL ROLE IN THE DEVELOPMENT OF AN EARLY DETECTION BLOOD-BASED TEST CALLED CANCERSEEK THAT CAN IDENTIFY THE PRESENCE OF MULTIPLE CANCERS. A 2020 LANDMARK STUDY, DEMONSTRATED CANCERSEEK SHOWED PROMISING RESULTS FOR EARLIER DETECTION AS PART OF ROUTINE MEDICAL CHECKS, ENABLING POTENTIALLY CURATIVE TREATMENT THAT COULD CHANGE PATIENT OUTCOMES. THE STUDY FOUND THAT THE TEST MORE THAN DOUBLED THE NUMBER OF CANCERS THAT WERE FIRST "SCREEN-DETECTED AND IDENTIFIED UNDIAGNOSED CANCERS IN 10 DIFFERENT ORGANS (INCLUDING SEVEN WITH NO CURRENT STANDARD-OF-CARE SCREENING). EXACT SCIENCE, WHICH ACQUIRED THE RIGHTS TO CANCERSEEK IN 2021, IS PREPARING TO INITIATE AN 80,000-PERSON REGISTRATION TRIAL AS A STEP TOWARD ACHIEVING FDA APPROVAL. - ARTIFICIAL INTELLIGENCE IS KEY TO DETECTING PANCREATIC CANCER EARLIER LUSTGARTEN-FUNDED RESEARCHERS AT JOHNS HOPKINS ALSO ARE USING ARTIFICIAL INTELLIGENCE TO DETECT PANCREATIC CANCER EARLIER. THROUGH THEIR RESEARCH, THEY'VE TRAINED COMPUTERS TO RECOGNIZE PATTERNS IN MEDICAL IMAGES TO DETECT PANCREATIC TUMORS ON CT SCANS AND IDENTIFY TUMORS MEASURING ONE CENTIMETER OR LESS, WHEN THEY MAY BE MISSED BY A DIAGNOSTICIAN, SO DIAGNOSIS AND SUBSEQUENT TREATMENT CAN BE STARTED MUCH SOONER. - COMPCYST TEST CAN PREVENT UNNECESSARY SURGERIES THE LUSTGARTEN-DEDICATED LABORATORY AT JOHNS HOPKINS IS DEVELOPING A TEST CALLED COMPCYST, WHICH COMBINES CLINICAL, RADIOLOGICAL, GENETIC AND PROTEIN MARKER INFORMATION TO CLASSIFY PANCREATIC CYSTS AND DETERMINE WHICH ONES REQUIRE SURGERY. THE LUSTGARTEN LABORATORY AT JOHNS HOPKINS IS WORKING TO FURTHER DEVELOP COMPCYST INTO A CLINICALLY APPROVED TEST.
FORM 990, PART III, LINE 4AIDENTIFYING NOVEL THERAPEUTIC APPROACHES: THE FOUNDATION'S THERAPEUTICS-FOCUSED RESEARCH PROGRAM WAS CREATED TO ENSURE A ROBUST AND FLOURISHING PIPELINE OF POTENTIAL TREATMENTS AND TO ENABLE COLLABORATION. TO DATE, THE THERAPEUTICS-FOCUSED RESEARCH PROGRAM HAS AWARDED 11 GRANTS TOTALING MORE THAN $12.3 MILLION. FUNDED PROJECTS ADDRESS FOUR KEY AREAS OF PANCREATIC CANCER BIOLOGY: - LEARNING HOW THE STROMA - THE SUPPORTIVE TISSUE SURROUNDING THE PANCREATIC TUMOR - MAY HELP PROTECT TUMORS FROM THE IMMUNE SYSTEM AND RESIST THERAPIES. - UNDERSTANDING AND DISCOVERING HOW TO BLOCK THE INFLAMMATORY SIGNALS THAT CAN LEAD TO PANCREATIC CANCER AND OTHER PANCREATIC DISEASES IN RESPONSE TO ENVIRONMENTAL CAUSES. - DETERMINING WAYS TO STOP TUMOR CELL GROWTH BY BLOCKING THE ABNORMAL METABOLIC PATHWAYS USED BY PANCREATIC CANCER CELLS. - PREVENTING THE SPREAD - OR METASTASIS - OF CANCER BY ISOLATING METASTATIC TRIGGERS IN CANCER CELLS AND THE STROMA. EXPANDING COLLABORATION WITH STAND UP TO CANCER: THE PANCREATIC CANCER COLLECTIVE (PCC), A JOINT INITIATIVE OF THE LUSTGARTEN FOUNDATION AND STAND UP TO CANCER, IS MAKING GROUNDBREAKING PROGRESS IN IDENTIFYING NEW WAYS TO TREAT PANCREATIC CANCER AND IMPROVING OUTCOMES FOR PATIENTS. THE COLLECTIVE HAS SUPPORTED RESEARCH LED BY MORE THAN 400 RESEARCH INVESTIGATORS AT APPROXIMATELY 70 PARTICIPATING INSTITUTIONS INCLUDING NEARLY 30 CLINICAL TRIALS. WORK BEGAN ON FOUR PROJECTS SUPPORTED THROUGH THE PCC'S "NEW THERAPIES CHALLENGE GRANTS." APPROVED FOR SECOND-ROUND FUNDING IN FY20, THESE POTENTIAL TREATMENTS BEGAN CLINICAL TRIALS IN FY21. IN FY21, THE COLLECTIVE PROVIDED NEW FUNDING FOR TWO ADDITIONAL IMMUNOTHERAPY CLINICAL TRIALS AS PART OF DR. ELIZABETH JAFFEE'S "CONVERGENCE DREAM TEAM TRANSLATIONAL RESEARCH GRANT": - $900,000 TO SUPPORT A STUDY LED BY PHIL GREENBERG, MD, FRED HUTCHINSON CANCER CENTER TO INVESTIGATE EFFICACY OF A TARGETED T-CELL RECEPTOR MEDIATED CELLULAR THERAPY TARGETING THE MESOTHELIN PROTEIN TO ELIMINATE PANCREATIC AND OVARIAN CANCER. - $422,854 TO SUPPORT A STUDY LED BY ROBERT D. SCHREIBER, MD, WASHINGTON UNIVERSITY, TO EXPLORE THE SAFETY AND IMMUNOTHERAPEUTIC POTENTIAL OF ADMINISTRATION OF PERSONALIZED NEOANTIGEN VACCINES TO PATIENTS WITH PANCREAS CANCER. THE PANCREATIC CANCER COLLECTIVE (PCC), A JOINT INITIATIVE OF THE LUSTGARTEN FOUNDATION AND STAND UP TO CANCER, IS MAKING GROUNDBREAKING PROGRESS IN IDENTIFYING NEW WAYS TO TREAT PANCREATIC CANCER AND IMPROVING OUTCOMES FOR PATIENTS. THE COLLECTIVE CONTINUES CONDUCTING NEARLY 30 CLINICAL TRIALS LED BY MORE THAN 400 RESEARCH INVESTIGATORS AT APPROXIMATELY 70 PARTICIPATING INSTITUTIONS. ADDRESSING EQUITY, DIVERSITY AND INCLUSION IN PANCREATIC CANCER RESEARCH: SOLVING THE COMPLEX PROBLEM OF PANCREATIC CANCER REQUIRES DIVERSITY OF THOUGHT, EDUCATION, TRAINING, BACKGROUND AND EXPERIENCE TO MOVE PROGRESS FORWARD. OUR COMMITMENT TO ENSURING EQUITY, DIVERSITY AND INCLUSION - ACROSS LUSTGARTEN-FUNDED RESEARCH AND THE SCIENTISTS WE SUPPORT - IS FOUNDATIONAL TO OUR MISSION TO CURE PANCREATIC CANCER. SUPPORTING DISTINGUISHED EARLY-CAREER SCIENTISTS HELPS ENSURE THEIR CONTINUED COMMITMENT TO STUDYING PANCREATIC CANCER. THE LUSTGARTEN FOUNDATION CREATED TWO CAREER DEVELOPMENT AWARDS TO INCREASE THE NUMBER OF EARLY-CAREER WOMEN AND UNDERREPRESENTED SCIENTISTS RECEIVING FUNDING FOR PANCREATIC CANCER RESEARCH. THE AWARDS SUPPORT INVESTIGATORS COMMITTED TO INCREASING OUR UNDERSTANDING AND TREATMENT OF THIS DISEASE. THE AWARDS HONOR THE LIVES AND LEGACIES OF TWO TRAILBLAZING AMERICANS LOST TO PANCREATIC CANCER - JUSTICE RUTH BADER GINSBURG AND CONGRESSMAN JOHN ROBERT LEWIS. EACH RECIPIENT IS AWARDED A THREE-YEAR, $300,000 GRANT FOR THEIR PANCREATIC CANCER RESEARCH. - CAREER DEVELOPMENT AWARD IN HONOR OF RUTH BADER GINSBURG WAS AWARDED TO DANNIELLE ENGLE, PHD, AN ASSISTANT PROFESSOR AT THE SALK INSTITUTE FOR BIOLOGICAL STUDIES. DR. ENGLE IS INVESTIGATING THE ROLE OF PANCREATITIS AND INFLAMMATION IN THE FORMATION OF PANCREATIC CANCER. - CAREER DEVELOPMENT AWARD IN HONOR OF JOHN ROBERT LEWIS WAS AWARDED TO AVERY D. POSEY JR., PHD, AND ASSISTANT PROFESSOR IN THE PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PENNSYLVANIA. DR. POSEY IS CONTINUING HIS RESEARCH TO INCREASE IMMUNE SYSTEM EFFECTIVENESS AT ATTACKING PANCREATIC CANCER. IN ADDITION, DR. POSEY WAS INVITED TO PRESENT AT THE INAUGURAL JUNETEENTH LUSTGARTENLIVE! WEBINAR.
FORM 990, PART VI, SECTION A, LINE 2CHARLES F. DOLAN, JAMES L. DOLAN AND QUENTIN DOLAN - FAMILY AND BUSINESS RELATIONSHIP. MARCIA LUSTGARTEN, ANDREW LUSTGARTEN AND JESSICA LUSTGARTEN COURTEMANCHE - FAMILY RELATIONSHIP.
FORM 990, PART VI, SECTION B, LINE 11BFORM 990 IS REVIEWED BY THE PRESIDENT FOR ACCURACY AND REASONABLENESS PRIOR TO SUBMISSION TO THE IRS. ADDITIONALLY A COMPLETE COPY OF THE FINAL RETURN IS PROVIDED TO ALL VOTING BOARD MEMBERS PRIOR TO FILING WITH THE IRS.
FORM 990, PART VI, SECTION B, LINE 12CTHE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY. THE WRITTEN POLICY REQUIRES ANNUAL DISCLOSURES BY ALL MEMBERS OF THE BOARD OF DIRECTORS, OFFICERS, AND KEY PERSONS OF ANY INTEREST THAT COULD GIVE RISE TO CONFLICT. THE ORGANIZATION REGULARLY AND CONSISTENTLY MONITORS AND ENFORCES THE COMPLIANCE OF THE CONFLICT OF INTEREST POLICY. IN THE INSTANCE WHERE A DIRECTOR HAS A CONFLICT, THEY ARE ASKED BY THE BOARD CHAIR TO RECUSE THEMSELVES FROM DELIBERATIONS, DECISIONS AND THE VOTE.
FORM 990, PART VI, SECTION B, LINE 15COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER AND THE PRESIDENT WAS REVIEWED AND APPROVED BY THE INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS IN 2021. THE REVIEW WAS UNDERTAKEN BY A THIRD-PARTY HUMAN RESOURCES CONSULTANT AND INCLUDED THE USE OF COMPARABILITY DATA WHICH WAS CONTEMPORANEOUSLY DOCUMENTED.
FORM 990, PART VI, SECTION C, LINE 19AUDITED FINANCIAL STATEMENTS ARE MADE AVAILABLE ON THE ORGANIZATION'S WEBSITE. IN ADDITION, GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND AUDITED FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.